Pravastatin for primary prevention of coronary heart disease

Kaplan-Meier analysis of the efficacy of pravastatin versus placebo in 6595 middle-aged men with hypercholesterolemia (mean serum cholesterol concentration 272 mg/dL [7.0 mmol/L]). At the end of the study, the men treated with pravastatin (red line) had a 32% reduction in definite nonfatal MI or death from CHD (top panel) and a 22% reduction in death from any cause (lower panel).